promotion of pharmaceutical products in the Territory that Janssen deems necessary or advisable to follow (including Janssen's compliance policies). 1.84 "Promotional Materials" has the meaning set forth in Section 3.4.2. 1.85 "Quarter End Date" has the meaning set forth in Section 1.16. 1.86 "Receiving Party" has the meaning set forth in Section 9.1.3. 1.87 "Regulatory Approval" means all technical, medical and scientific licenses, registrations, authorizations and approvals (including Marketing Approvals and labeling approvals) of all applicable Regulatory Authorities necessary for the commercial distribution, marketing, promotion, offer for sale, use, import and sale of a pharmaceutical product in a regulatory jurisdiction. 1.88 "Regulatory Authority" means any authority, agency, commission, official or other instrumentality inside or outside the Territory, including the FDA, having jurisdiction over the manufacture of Product for sale in the Territory, or over the commercial distribution, marketing, promotion, offer for sale, use, import or sale of the Product in the Territory. 1.89 "Remediation Plan" has the meaning set forth in Section 3.2.4(b). 1.90 "Sales Force" has the meaning set forth in Section 3.3.2(a). 1.91 "Sales Representative" means a sales representative used by Company to perform Details of the Product for the Initial Indication to Health Care Professionals in the Territory. Sales Representative shall not include any key account manager, medical science liaison or regional sales manager. 1.92 "Second Position Detail" means, with respect to any product, a detail or presentation that is dedicated solely to such product and constitutes at least 30% of the total presentation time for all products presented during a Call in which such product is the second product presented to the health care professional. 1.93 "Service Fee" has the meaning set forth in Section 5.1. 1.94 "Start Date" means the first date upon which Sales Representatives are able to Detail the Product in accordance with